We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+34.16%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$913M
AUM Growth
+$115M
Cap. Flow
-$67.2M
Cap. Flow %
-7.37%
Top 10 Hldgs %
28.56%
Holding
108
New
15
Increased
30
Reduced
36
Closed
14

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$8.67M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$7.88M
3
ISRG icon
Intuitive Surgical
ISRG
+$6.74M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.19M
5
LIVN icon
LivaNova
LIVN
+$6.07M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.5M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.3M
3
TMO icon
Thermo Fisher Scientific
TMO
+$11.1M
4
COR icon
Cencora
COR
+$8.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.67M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.09%
3 Energy 0.09%
4 Technology 0.09%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
101
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-10,778
Closed -$272K
HMSY
102
DELISTED
HMS Holdings Corp.
HMSY
– –
-98,300
Closed -$3.39M
RARX
103
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-244,000
Closed -$5.77M
DPLO
104
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-1,060,000
Closed -$5.19M
ACHN
105
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-277,800
Closed -$1M
ARQL
106
DELISTED
Arqule Inc
ARQL
– –
-200,000
Closed -$1.43M
MDCO
107
DELISTED
Medicines Co
MDCO
– –
-153,000
Closed -$7.65M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rhenman & Partners Asset Management held 108 positions worth $913M, up 14% from $798M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $67.2M in Q4 2019, closing 14 positions and reducing 36 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Axonics, Inc. Common Stock worth $9.14M.

  • Rhenman & Partners Asset Management's largest Q4 2019 buy was Axonics, Inc. Common Stock: 330,000 shares worth $9.14M.
  • Rhenman & Partners Asset Management added most to Guardant Health in Q4 2019, an estimated $8.67M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2019 reduction was CVS Health, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited Thermo Fisher Scientific in Q4 2019, selling an estimated $11.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $913M portfolio in Q4 2019.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 14 in Q4 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $913M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.